Akebia Therapeutics Inc. [NASDAQ: AKBA] plunged by -$0.06 during the normal trading session on while it closed the day at $1.26. Akebia Therapeutics Inc. stock has also loss -8.03% of its value over the past 7 days. However, AKBA stock has declined by -23.17% in
Akebia Therapeutics Inc. [NASDAQ: AKBA] plunged by -$0.04 during the normal trading session on while it closed the day at $1.33. Akebia Therapeutics Inc. stock has also loss -4.32% of its value over the past 7 days. However, AKBA stock has declined by -11.33% in
Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 0.72% or 0.01 points to close at $1.40 with a heavy trading volume of 4122480 shares. The daily chart for AKBA points out that the company has recorded 54.30% gains over the past six months. If we look at
Akebia Therapeutics Inc. [NASDAQ: AKBA] jumped around 0.02 points on Wednesday, while shares priced at $1.56 at the close of the session, up 1.30%. The company report on April 2, 2024 at 4:05 PM that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics Inc. [NASDAQ: AKBA] slipped around -0.41 points on Thursday, while shares priced at $1.83 at the close of the session, down -18.30%. The company report on March 27, 2024 at 8:26 PM that Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the
Akebia Therapeutics Inc. [NASDAQ: AKBA] slipped around -0.21 points on Tuesday, while shares priced at $2.00 at the close of the session, down -9.50%. Compared to the average trading volume of 2.94M shares, AKBA reached a trading volume of 10110587 in the most recent trading
Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 11.18% or 0.19 points to close at $1.89 with a heavy trading volume of 9473963 shares. The company report on March 14, 2024 at 4:15 PM that Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and
Akebia Therapeutics Inc. [NASDAQ: AKBA] traded at a low on Wednesday, posting a -6.88 loss after which it closed the day’ session at $1.49. The company report on March 1, 2024 at 4:05 PM that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 8.61% on the last trading session, reaching $1.64 price per share at the time. The company report on February 2, 2024 at 4:05 PM that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Akebia Therapeutics®, Inc. (Nasdaq:
Akebia Therapeutics Inc. [NASDAQ: AKBA] plunged by -$0.06 during the normal trading session on while it closed the day at $1.47. The company report on February 2, 2024 at 4:05 PM that Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Akebia Therapeutics®, Inc.
© 2024, Powered by Smart TechOne
